LOCOID LIPOCREAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOCOID LIPOCREAM (LOCOID LIPOCREAM).
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
| Metabolism | Hydrocortisone butyrate undergoes hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4) and other esterases to inactive metabolites, including hydrocortisone and butyric acid. Subsequent glucuronidation and sulfation occur before renal excretion. |
| Excretion | Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites |
| Half-life | Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing |
| Protein binding | Hydrocortisone butyrate: ~88-92% bound to corticosteroid-binding globulin (CBG) and albumin |
| Volume of Distribution | Vd: ~0.3-0.5 L/kg (estimated systemic absorption from topical application; low Vd indicates limited tissue distribution in systemic circulation) |
| Bioavailability | Topical: ~1-5% systemically absorbed through intact skin; higher (up to 10-15%) if applied to inflamed, denuded, or occluded skin |
| Onset of Action | Topical: measurable vasoconstriction within 1-2 hours; clinical effect (e.g., reduced erythema) within 3-5 days of regular use |
| Duration of Action | Topical: vasoconstriction persists 6-8 hours after single application; clinical improvement maintained with twice-daily application |
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required. |
| Liver impairment | No dosage adjustment required. |
| Pediatric use | Apply a thin layer to affected area once daily. Maximum treatment duration: 7 days. Avoid prolonged use and occlusive dressings. |
| Geriatric use | Apply a thin layer to affected area twice daily. Limit use to shortest duration possible due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOCOID LIPOCREAM (LOCOID LIPOCREAM).
| Breastfeeding | Minimal systemic absorption from topical application; M/P ratio not established. Short-term, small area use is likely safe. Avoid application to breast area before nursing to prevent infant ingestion. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk during pregnancy due to minimal systemic absorption. However, prolonged use of potent or large amounts may increase risk of low birth weight (LBW) and preterm delivery. First trimester: no evidence of teratogenicity; second/third trimester: prolonged use associated with LBW and preterm delivery. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to hydrocortisone butyrate or any component of the formulation.","Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis).","Application to the external ear if the eardrum is perforated (risk of ototoxicity)."]
| Precautions | ["Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, especially in pediatric patients, patients with extensive disease, or with prolonged use on occluded areas.","Local adverse reactions include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria.","Prolonged use may increase the risk of cataracts or glaucoma if applied to periorbital area.","Use with caution in patients with skin atrophy, bacterial/fungal/viral infections, or impaired circulation.","Not for ophthalmic, oral, or intravaginal use."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of adrenal suppression with prolonged use. No specific fetal monitoring required, but assess fetal growth if used extensively in second/third trimester. |
| Fertility Effects | No known adverse effects on fertility from topical corticosteroids. |